MedTrace Logo

Heart and Estrogen-Progestin Replacement Study (HERS)

NCT00319566 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2430

Last updated 2006-04-27

No results posted yet for this study

Summary

The purpose of the study is to determine whether hormone replacement therapy in post menopausal women with coronary artery disease prevents future heart attacks or death from coronary heart disease.

Conditions

Interventions

DRUG

Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily

Sponsors & Collaborators

Principal Investigators

  • Stephen Hulley · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-07-31
Completion
2001-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319566 on ClinicalTrials.gov